Traded Feb 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Jan 12, 2026 · Filed Jan 14, 2026
United Therapeutics's PRESIDENT AND COO sold $7.01M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$7,012,769
Shares × reported transaction price
75 days after results of Oct 29, 2025, 44 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.3% | −0.7% | −0.5% |
| 30 days | −0.4% | −1.3% | +0.8% |
| 90 days | +21.6% | +0.6% | +21.0% |
| 180 days | +12.6% | +8.5% | +4.1% |
Past results only. Not a forecast.
Traded Feb 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Michael Benkowitz (PRESIDENT AND COO) sold ~$6.94M of United Therapeutics
Scheduled in advanceTraded Feb 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.